Targeted therapies have shown significant promise in reducing relapse rates in high-risk non-Hodgkin’s lymphoma (NHL) by specifically attacking cancer cells while sparing normal tissues, thereby improving treatment efficacy and patient outcomes. These therapies include monoclonal antibodies, antibody-drug conjugates, bispecific antibodies,…
Clinical trial designs for older adults with non-Hodgkin’s lymphoma (NHL) adapt in several important ways to address the unique challenges and needs of this population. Older adults often have different health profiles, including multiple chronic conditions, altered drug metabolism, and…
Non-Hodgkin’s lymphoma (NHL) research is increasingly shedding light on why survival rates vary so widely among different populations, revealing a complex interplay of biological, clinical, and social factors. Understanding these disparities requires looking beyond just the disease itself to how…
Rehabilitation plays a crucial and multifaceted role after a stem cell transplant for non-Hodgkin’s lymphoma (NHL), addressing the complex physical, emotional, and functional challenges patients face during recovery. Stem cell transplantation is an intensive treatment that involves high-dose chemotherapy or…
Cognitive rehabilitation can offer meaningful benefits to survivors of non-Hodgkin’s lymphoma (NHL) who experience cognitive difficulties following their cancer treatment. Many NHL survivors report problems commonly referred to as “chemobrain” or cancer-related cognitive impairment, which include challenges with memory, attention,…
Non-Hodgkin’s lymphoma (NHL) research increasingly recognizes the critical importance of addressing mental health support alongside physical treatment. This is because a diagnosis of NHL often brings profound emotional and psychological challenges, including shock, fear, anxiety, grief, and a sense of…
Non-Hodgkin’s lymphoma (NHL) survivors can indeed face lifelong neurological risks, which arise from a complex interplay of the disease itself, its treatments, and immune-related complications. These neurological issues may persist long after remission and significantly affect survivors’ quality of life.…
Palliative care research plays a crucial and multifaceted role in the management of advanced non-Hodgkin’s lymphoma (NHL), focusing on improving quality of life, symptom control, and aligning treatment with patient goals throughout the disease trajectory. Unlike curative treatments that primarily…
Frailty scoring can significantly improve treatment decisions in elderly patients with non-Hodgkin’s lymphoma by providing a clearer picture of their overall health status, physiological reserve, and vulnerability to treatment-related complications. Unlike chronological age alone, frailty scoring assesses multiple dimensions such…
Non-Hodgkin’s lymphoma (NHL) research addressing coexisting dementia care is a complex and evolving field that integrates oncology, neurology, and geriatric medicine to improve outcomes for patients facing both conditions simultaneously. NHL is a diverse group of blood cancers originating in…